Open AccessAssociation of MSH6 mutation with glioma susceptibility, drug resistance and progression
Author(s) -
Chaoran Xie,
Song Huang,
Nu Zhang,
Shiting Li,
Xiangyu Wei,
Xiaohang Zheng
Publication year - 2016
Publication title -
molecular and clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.442
H-Index - 7
eISSN - 2049-9469
pISSN - 2049-9450
DOI - 10.3892/mco.2016.907
Subject(s) - msh6 , msh2 , biology , germline mutation , temozolomide , cancer research , mutation , genetics , dna mismatch repair , somatic hypermutation , glioma , dna repair , gene , b cell , antibody
MutS homolog 6 (MSH6) is one of the mismatch repair proteins and is encoded by the MSH6 gene, which is located on chromosome 2 and is 23,806 bp in length, including 10 exons and 83 untranslated regions. The MSH6 protein consists of 1,358 amino acid residues and forms a heterodimer with another mismatch repair protein, MSH2. The MSH2-MSH6 heterodimeric complex is able to recognize base-base substitution and single-base insertion/deletion mismatches. Germline mutations of MSH6 lead to high susceptibility to glioma, as well as a number of benign or malignant tumors in other organs. However, somatic MSH6 mutations are not associated with susceptibility to glioma. Somatic MSH6 mutations usually follow temozolomide treatment and result in resistance to temozolomide. Subsequently, MSH6 mutations cause a hypermutation in the glioma cell genome, which may accelerate tumor progression.